Study Finds No Increased Cancer Risk in Rheumatology Patients with History of Malignancy Taking DMARDS and TNF Inhibitors

New research presented this week at ACR Convergence, the organization’s annual meeting, found no significant difference in cancer risk in patients with rheumatic disease & a history of malignancy taking biologic or targeted synthetic DMARDs compared to those treated with TNF inhibitors.

Fear of Side Effects, Including Rheumatic Disease Flares, Driving COVID-19 Vaccine Hesitancy Among Some Patients

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that in Alabama, one in 10 racial or ethnic minority patients with a rheumatic disease in a large rheumatology clinic said they were unlikely to get vaccinated against COVID-19.

“My Disease May Be Invisible, But I’m Not”: Patients Tell Their Stories During Rheumatic Disease Awareness Month

The American College of Rheumatology (ACR) and Simple Tasks™ will recognize the fifth annual Rheumatic Disease Awareness Month (RDAM) this September with an awareness campaign that focuses on amplifying patient voices and experiences.